Open Label, Interventional Single Arm Study Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies.

The article discusses a clinical trial, NCT06787482, evaluating a novel peptide-based therapy for retinal dystrophies, age-related macular degeneration (AMD), and diabetic retinopathy (DR). The therapy involves peptides derived from fetal tissues, mesenchymal stem cells, and bioactive growth factors administered sublingually. The study aims to assess safety, tolerability, and effects on retinal function and structure, with secondary objectives focusing on visual acuity, retinal thickness, vascular health, and disease biomarkers. The trial involves 150 adults divided into three cohorts and will last for 12 months, aiming to provide a non-invasive treatment for debilitating retinal conditions. [Extracted from the article]